R.J.H.M. van der Straaten

Author

Also Known As

R. J. H. M. van der Straaten, R.J.H.M. van der Straaten, Robert J. H. M. van der Straaten, Robert J.H.M. Van Der Straaten

Publications

344

Citations

H-Index

Concepts

All Affiliations

Leiden University Medical Center University Medical Center Utrecht Amsterdam UMC Location University of Amsterdam Maastricht University Leiden University

About

R.J.H.M. van der Straaten is an author at Leiden University Medical Center specializing in medicine, oxidative stress, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	100
2	Biochemistry	2	2	59
3	Pharmacology	2	2	62
4	Neuroscience	1	1	38
5	Pathology	1	1	41

R.J.H.M. van der Straaten

Publications

338

Citations

H-Index

Page 1

	Year	Citations
Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis H M Albers, Judith A.M. Wessels, R.J.H.M. van der Straaten, Arthritis Care & Research	2008	136
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study Hans Gelderblom, Jean‐Yves Blay, Beatrice Seddon, European Journal of Cancer Brostallicin Versus DoxorubicinPhase IiMedicinePharmacologyPathology	2013	41
Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy Dyah Aryani Perwitasari, Judith A.M. Wessels, R.J.H.M. van der Straaten, Japanese Journal of Clinical Oncology	2011	39
Arsenic metabolites affect expression of the neurofilament and tau genes: An in-vitro study into the mechanism of arsenic neurotoxicity A. Vahidnia, R.J.H.M. van der Straaten, Fred P.H.T.M. Romijn, Toxicology in Vitro Neurodegenerative DiseasesBiochemistryTau GenesNeurogeneticsToxicology	2007	38
Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease Maurits E. L. Arbouw, Kris L. L. Movig, Toine C. G. Egberts, European Journal of Clinical Pharmacology	2009	29
Mechanism of arsenic-induced neurotoxicity may be explained through cleavage of p35 to p25 by calpain A. Vahidnia, R.J.H.M. van der Straaten, Fred P.H.T.M. Romijn, Toxicology in Vitro BiochemistryMedicineNeuropharmacologyToxicologyNeuroprotection	2008	21
Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype H. J. M. van Kan, Leonard H. van den Berg, Geert Jan Groeneveld, Biopharmaceutics & Drug Disposition	2007	12
Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients Lieke H. van Huis‐Tanja, Ewoud Ewing, R.J.H.M. van der Straaten, Pharmacogenetics and Genomics	2015	11
Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing Anyue Yin, Madeleine H. T. Ettaieb, Jesse J. Swen, Clinical Pharmacokinetics	2020	11

Page 1